Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Oct 31, 2026 → Oct 31, 2027
See other at-risk trials from National Cancer Institute (NCI)

Record History

The 50 most recent of 128 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Oct 31, 2026 to Oct 31, 2027
  2. Eligibility criteria expanded, about 58 words
    • Secondary endpoints: details revised at 4 of 5 entries
    • Study description revised
    • Site details revised at 9 of 42 sites
  3. Study sites revised (42)v126
  4. Re-verified, no change to tracked fieldsv125
  5. Study sites revised (42)v124
Show 45 earlier versionsHide 45 earlier versions
  1. 4 versions Re-verified since Apr 8, 2026, no change to tracked fieldsv120-v123
  2. Primary and study completion dates: Oct 31, 2025 to Oct 31, 2026v119
  3. 2 versions Re-verified since Apr 16, 2025, no change to tracked fieldsv117-v118
  4. Eligibility criteria expanded, about 18 words
    • Study description expanded, about 6 words
    v116
  5. 4 versions Re-verified since Jun 25, 2024, no change to tracked fieldsv112-v115
  6. Study description expanded, about 3 wordsv111
  7. Study sites: 45 to 42v110
  8. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 45 of 45 sites
    v109
  9. 2 versions Re-verified since Mar 5, 2024, no change to tracked fieldsv107-v108
  10. Site contacts updated at 1 of 45 sitesv106
  11. Study sites revised (45)v105
  12. Site details revised at 1 of 45 sitesv104
  13. Site details revised at 3 of 45 sitesv103
  14. Site details revised at 4 of 45 sitesv102
  15. Re-verified, no change to tracked fieldsv101
  16. Primary and study completion dates: Oct 31, 2023 to Oct 31, 2025v100
  17. Start date: Mar 3, 2017 to Apr 25, 2017v99
  18. Site details revised at 1 of 45 sitesv98
  19. Re-verified, no change to tracked fieldsv97
  20. Study sites revised (45)v96
  21. Re-verified, no change to tracked fieldsv95
  22. Site details revised at 1 of 45 sitesv94
  23. Re-verified, no change to tracked fieldsv93
  24. Site details revised at 1 of 45 sitesv92
  25. Re-verified, no change to tracked fieldsv91
  26. Enrollment target: 62 to 63
    • Eligibility criteria expanded, about 680 words
    • Site details revised at 1 of 45 sites
    v90
  27. Study sites: 43 to 45v89
  28. Primary and study completion dates: Oct 31, 2022 to Oct 31, 2023v88
  29. Interventions: Atezolizumab (Drug), Bevacizumab (Biological) to Atezolizumab (Drug), Bevacizumab (Biological), Biospecimen Collection (Procedure), Computed Tomography (Procedure)
    • Eligibility criteria expanded, about 18 words
    • Study description expanded, about 42 words
    v87
  30. Re-verified, no change to tracked fieldsv86
  31. Site details revised at 2 of 43 sitesv85
  32. Site details revised at 6 of 43 sitesv84
  33. Trial status: Suspended to Recruiting
    • Site details revised at 43 of 43 sites
    v83
  34. 2 versions Re-verified since May 28, 2022, no change to tracked fieldsv81-v82
  35. Trial status: Recruiting to Suspended Sponsor's reason: Other - To address contract issues.v80
  36. Re-verified, no change to tracked fieldsv79
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial studies how well atezolizumab or atezolizumab plus bevacizumab works in treating patients with alveolar soft part sarcoma that has not been treated, has spread from where it started to other places in the body (advanced) and cannot be removed by surgery (unresectable). Atezolizumab works by unblocking the immune system, allowing the immune system cells to recognize and then attack tumor cells. Bevacizumab works by controlling the growth of new blood vessels. Giving atezolizumab alone or atezolizumab with bevacizumab may shrink the cancer.
Trial Details
NCT Number NCT03141684
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)		 Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma
Related terms Sarcoma, Alveolar Soft Part
Enrollment 63 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov